SWG Educational Activities

EHA-SWG meetings:

  • Planning for an EMSCO meeting in 2023 has started in 2022, which will be held in Nice on Oct 20-21 2023

Presentations at national and international meetings:

Contributions to EHA2021

  • A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO LOWER-RISK MDS IN ESA-NAIVE PATIENTS REQUIRING RBC TRANSFUSIONS (THE COMMANDS TRIAL). Author(s): Matteo Della Porta et al. EHA Library. Della Porta M. 06/09/21; 324296; PB1619
  • COMPARISON OF DOSE MODIFICATION STRATEGIES TO ADDRESS EXPECTED HEMATOLOGIC TOXICITIES IN TREATMENT-NAÏVE HIGHER-RISK (HR) MDS PATIENTS TREATED WITH VENETOCLAX + AZACITIDINE. Author(s): Uwe Platzbecker et al. EHA Library. Platzbecker U. 06/09/21; 325684; EP926
  • EFFICACY OF IMETELSTAT IS INDEPENDENT OF MOLECULAR SUBTYPES IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESA). Author(s): Uwe Platzbecker et al. EHA Library. Platzbecker U. 06/09/21; 325668; EP910
  • LUSPATERCEPT REDUCES RED BLOOD CELL TRANSFUSIONS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES REGARDLESS OF BASELINE TRANSFUSION BURDEN IN THE MEDALIST STUDY. Author(s): Guillermo Garcia-Manero et al. EHA Library. Garcia-Manero G. 06/09/21; 325678; EP920
  • BENEFIT OF CONTINUING LUSPATERCEPT THERAPY IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO DID NOT ACHIEVE RED BLOOD CELL TRANSFUSION INDEPENDENCE BY WEEK 25 IN THE MEDALIST STUDY. Author(s): Ulrich Germing et al. EHA Library. Germing U. 06/09/21; 325673; EP915

Contributions to EHA2022

  • FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP. Uwe Platzbecker et al. EHA Library. Author(s): Platzbecker U. 06/10/22; 357392; P529
  • CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES. Anne Sophie Kubasch et al. EHA Library. Author(s): Sophie Kubasch A. 06/12/22; 357033; S169
  • LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL. Author(s): Pierre Fenaux et al. EHA Library. Fenaux P. 06/10/22; 357640; P778

Contributions to ASH2021

  • On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Valeria Santini et al. Blood (2021) 138 (Supplement 1): 2598.
  • Predicting Early Relapse for Patients with Multiple Myeloma through Machine Learning. Anne Sophie Kubasch et al. Blood (2021) 138 (Supplement 1): 2953.
  • Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution. Judith S. Hecker et al. Blood (2021) 138 (Supplement 1): 3278.
  • Application of AI-Based Analytical Approaches for Multiplex Immunophenotyping of SF3B1 -Mutant Myelodysplastic Syndrome Subtype. Susann Winter et al. Blood (2021) 138 (Supplement 1): 1512.
  • Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival. Uta Oelschlaegel et al. Blood (2021) 138 (Supplement 1): 2603.
  • CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. Pierre Peterlin et al. Blood (2021) 138 (Supplement 1): 243.
  • Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset. David Bowen et al. Blood (2021) 138 (Supplement 1): 4671.
  • A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial). Arsène Mékinian et al. Blood (2021) 138 (Supplement 1): 3697.
  • On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Valeria Santini et al. Blood (2021) 138 (Supplement 1): 2598.
  • Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk". Marie Sebert et al. Blood (2021) 138 (Supplement 1): 1842.
  • Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group. Marie Sebert et al. Blood (2021) 138 (Supplement 1): 62.
  • Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS): The Ideal Phase 2 Study By the GFM Group. Lionel Ades et al. Blood (2021) 138 (Supplement 1): 63.

Contributions to ASH2022

  • Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes. Elena Riva et al. Blood (2022) 140 (Supplement 1): 4001–4004.
  • Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes. Elisabetta Sauta et al. Blood (2022) 140 (Supplement 1): 1121–1124.
  • Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial. Félix López Cadenas et al. Blood (2022) 140 (Supplement 1): 1109–1111.
  • Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Uwe Platzbecker et al. Blood (2022) 140 (Supplement 1): 1106–1108.
  • Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study. Uwe Platzbecker et al. Blood (2022) 140 (Supplement 1): 6971–6973.
  • Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial. Valeria Santini et al. Blood (2022) 140 (Supplement 1): 4079–4081.
  • Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Uwe Platzbecker et al. Blood (2022) 140 (Supplement 1): 1106–1108.
  • Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study. Uwe Platzbecker et al. Blood (2022) 140 (Supplement 1): 6971–6973.
  • Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes. Elena Riva et al. Blood (2022) 140 (Supplement 1): 4001–4004.
  • Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study. Uwe Platzbecker et al. Blood (2022) 140 (Supplement 1): 9808–9810.
  • Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics. Marie Schneider et al. Blood (2022) 140 (Supplement 1): 4011–4012.
  • DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation. David Rombaut et al. Blood (2022) 140 (Supplement 1): 215–216.
  • Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach? Sofía M Toribio Castelló et al. Blood (2022) 140 (Supplement 1): 9740–9743.
  • Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). Valeria Santini et al. Blood (2022) 140 (Supplement 1): 1340–1342.
  • Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases. Inga Mandac Smoljanovic et al. Blood (2022) 140 (Supplement 1): 9802–9803.

Collaborations on international projects promoted by or involving the SWG:

  • Continued involvement HARMONY and EuroBloodNet EU initiatives.
  • Several common clinical trials in planning phase (in both LR and HR MDS), partly involving translational programs

Other activities:

  • Involvement of SWG members in the new WHO classification (2022)
  • Involvement of SWG members in the new Molecular International Prognostic Scoring System for MDS (IPSS-M)
  • Several SWG members have acted as reviewers for the EHA congresses
  • Individual study group meetings, MDS workshops etc. on country level
  • Country level patient days